Search research articles
Contact Us
Filters
Showing results (101-110 of 116) with videos related to
Page
of 12
Sort By:
Anti-Cancer Drugs
|
March 31, 2025
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study
Selin Akturk Esen, Ismet Seven, Gonca Akdere Ates, et al.
Medicine
|
February 3, 2017
Miliary tuberculosis: Epidemiologicaland clinical analysis of large-case series from moderate to low tuberculosis endemic Country
Ali Mert, Ferhat Arslan, Tülin Kuyucu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
Arif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
Arif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
The Journal of Antimicrobial Chemotherapy
|
June 1, 2023
Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study
Abdullah Tarık Aslan, Alexis Tabah, Bahadır Köylü, et al.
Journal of Clinical Medicine
|
June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study
Serhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Scientific Reports
|
October 16, 2025
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study
Safa Can Efil, Burak Bilgin, Irem Bilgetekin, et al.
The Lancet. Infectious Diseases
|
October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
David L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
JAMA
|
September 13, 2018
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial
Patrick N A Harris, Paul A Tambyah, David C Lye, et al.
Medical Mycology
|
June 24, 2024
Factors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study
Meyha Sahin, Mesut Yilmaz, Ali Mert, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 116) with videos related to
Sort By:
Page
of 12
Anti-Cancer Drugs
|
March 31, 2025
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study
Selin Akturk Esen, Ismet Seven, Gonca Akdere Ates, et al.
Medicine
|
February 3, 2017
Miliary tuberculosis: Epidemiologicaland clinical analysis of large-case series from moderate to low tuberculosis endemic Country
Ali Mert, Ferhat Arslan, Tülin Kuyucu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
Arif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group
Arif Akyildiz, Melis Gultekin, Ecem Yigit, et al.
The Journal of Antimicrobial Chemotherapy
|
June 1, 2023
Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study
Abdullah Tarık Aslan, Alexis Tabah, Bahadır Köylü, et al.
Journal of Clinical Medicine
|
June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group Study
Serhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Scientific Reports
|
October 16, 2025
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study
Safa Can Efil, Burak Bilgin, Irem Bilgetekin, et al.
The Lancet. Infectious Diseases
|
October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
David L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
JAMA
|
September 13, 2018
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial
Patrick N A Harris, Paul A Tambyah, David C Lye, et al.
Medical Mycology
|
June 24, 2024
Factors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study
Meyha Sahin, Mesut Yilmaz, Ali Mert, et al.
Page
of 12